Related Experiment Video
Updated: Jul 14, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
Immunodeficiency and autoimmunity in 22q11.2 deletion syndrome
A McLean-Tooke1, G P Spickett1, A R Gennery1
1Department of Immunology, Royal Victoria InfirmaryDepartment of Paediatric Immunology, Newcastle General Hospital, Newcastle-Upon-Tyne, UK.
Abstract:
22q11.2 deletion syndrome is the commonest chromosome deletion syndrome. 22q11.2 deletion may result in variable clinical phenotypes which may differ even between patients with identical deletions. Abnormal pharyngeal arch development results in defects in the development of the parathyroid glands, thymus and conotruncal region of the heart. Defective thymic development is associated with impaired immune function. 'Complete' DiGeorge syndrome with total absence of the thymus and a severe T-cell immunodeficiency accounts for <0.5% of patients. The majority of patients with 22q11.2 deletion syndromes have 'partial' defects with impaired thymic development rather than complete absence with variable defects in T-cell numbers. Immunodeficiency in these patients is not solely due to T-cell deficiency and abnormalities of T-cell clonality or impairment of proliferative responses may play a role. Humoral deficiencies including defects in the B-cell compartment have also been identified in these patients. 22q11.2 deletion syndrome patients are at increased risk of a variety of autoimmune diseases. A number of immune defects may predispose to the development of autoimmunity in these patients including increased infection, impaired development of natural T-regulatory cells and impaired thymic central tolerance.
Related Concept Videos
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
What is the Immune System?
Type I Diabetes II: Pathophysiology
Humoral Immune Responses
Type I Diabetes I: Introduction
